Patenting Genes: What Does Association for Molecular Pathology V. Myriad Genetics Mean for Genetic Testing and Research?

Association for Molecular Pathology et al. v. Myriad Genetics, Inc., et al. 133 S. Ct. 2107 (June 13, 2013).

American Cancer Society. Cancer facts and figures 2013 [cited 2013 Nov 30]. Available from: URL: http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2013/index

National Cancer Institute, National Institutes of Health (US). Cancer trends progress report—2011/2012 update. Bethesda (MD): NCI, NIH, Department of Health and Human Services (US); 2012 Also available from: URL: http://progressreport.cancer.gov [cited 2013 Nov 30].

National Cancer Institute, National Institutes of Health (US). Fact sheet: BRCA1 and BRCA2: cancer risk and genetic testing [cited 2013 Nov 30]. Available from: URL: http://www.cancer.gov/cancertopics/factsheet/Risk/BRCA

Domchek SM Friebel TM Singer CF Evans DG Lynch HT Isaacs C Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010; 304:967–75.

Mullin J . Ambry hits back at Myriad's “bad faith enforcement” of breast cancer gene patents. Ars Technica 2013 Aug 7 [cited 2013 Nov 30]. Available from: URL: http://arstechnica.com/tech-policy/2013/08/ambry-hits-back-at-myriads-bad-faith-enforcement-of-breast-cancer-gene-patents

Krench M . New Supreme Court decision rules that cDNA is patentable—what it means for research and genetic testing. Scientific American 2013 Jul 9 [cited 2013 Nov 30]. Available from: URL: http://blogs.scientificamerican.com/guest-blog/2013/07/09/new-supreme-court-decision-rules-that-cdna-is-patentablewhat-it-means-for-research-and-genetic-testing

Association for Molecular Pathology v. United States Patent and Trademark Office, 669 F. Supp. 2d 365, 385-392 (SDNY 2009).

Association for Molecular Pathology v. United States Patent and Trademark Office, 689 F.3d 1303, 1323 (CA Fed. 2012).

Pollack A . After patent ruling, availability of gene tests could broaden. The New York Times 2013 Jun 13 [cited 2013 Nov 30]. Available from: URL: http://www.nytimes.com/2013/06/14/business/after-dna-patent-ruling-availability-of-genetic-tests-could-broaden.html?hp&_r=0

University of Utah Research Foundation, et al. v. Ambry Genetics Corp. Case No. 2:13-cv-00640-RJS (D. Utah, filed July 9, 2013).

Jaslow R . Supreme Court's gene patent ruling could boost patient care, experts say. CBS News 2013 Jun 13 [cited 2013 Nov 30]. Available from: URL: http://www.cbsnews.com/8301-204_162-57589253/supreme-courts-gene-patent-ruling-could-boost-patient-care-experts-say

Khan A . Doctors: Supreme Court BRCA gene patent ruling benefits patients. Los Angeles Times 2013 Jun 13 [cited 2013 Nov 30]. Available from: URL: http://www.latimes.com/news/science/sciencenow/la-sci-sn-supreme-court-gene-patent-brca-celebrate-20130613,0,1238521.story

Cho M Illangasekare S Weaver MA Leonard DG Merz JF . Effects of patents and licenses on the provision of clinical genetic testing services. J Mol Diagn 2003; 5:3–8.

Resnick B . Why is Myriad Genetics still filing patent suits for breast-cancer tests? National Journal 2013 Aug 8 [cited 2013 Nov 30]. Available from: URL: http://www.nationaljournal.com/healthcare/why-is-myriad-genetics-still-filing-patent-suits-for-breast-cancer-tests-20130808

Rosenfeld JA Mason CE . Pervasive sequence patents cover the entire human genome. Genome Med 2013; 5:27.